Peginterferon alfa-2b
A recombinant signalling protein drug.
General information
Peginterferon alfa-2b is a recombinant type I interferon used for hepatitis C virus infection treatment. It activates JAK/STAT signalling pathway, suppresses viral replication, reduces cell proliferation, and induces apoptosis. It displays anti-angiogenic effects, as well. Peginterferon alfa-2b is associated with severe adverse effects (DrugBank). It is on the World Health Organization Model List of Essential Medicines.
Peginterferon alfa-2b on Wikipedia
Synonyms
Pegylated interferon alpha-2b; PEG IFN-α2b
Marketed as
PEGINTRON
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Efficacy and Safety of Pegylated Interferon alfa-2b in Moderate COVID-19: A phase II, randomized, controlled, open-label study
Protein factor Randomized controlled open trial Moderate severity |
Moderate COVID-19 patients | 3.20 | Statistically significantly more patients in the treatment group achieved clinical improvement by day 15 compared to control. A lower proportion of treated patients were RT-PCR-positive for SARS-CoV-2 on days 7 and 14. Sample size: 20 + 20 control. Dosage: A single subcutaneous dose of 1 µg/kg. Primary endpoint: Improvement in clinical status on day 15 on an ordinal scale. |
Mar/10/2021 |
